Breaking News Instant updates and real-time market news.

DBVT

DBV Technologies

$8.57

-0.39 (-4.35%)

04:46
05/14/19
05/14
04:46
05/14/19
04:46

DBV Technologies announces departure of Deputy CEO David Schilansky

DBV Technologies announced that its Deputy Chief Executive Officer and Principal Financial Officer, David Schilansky, has decided to leave the company to pursue other professional opportunities. David will remain at the Company through August 2019. While a new Chief Financial Officer search is underway, DBV will not fill the Deputy CEO role following Schilansky's departure.

DBVT DBV Technologies
$8.57

-0.39 (-4.35%)

03/06/19
JMPS
03/06/19
NO CHANGE
Target $20
JMPS
Outperform
JMP Securities not surprised by leadership changes at DBV Technologies
JMP Securities Liisa Bayko said she is not overly surprised to see high-level management changes at DBV Technologies given the important juncture the company is at and the need to assuage investor concerns. DBV also reported quarterly results and updated its cash position, guiding that its $141M on hand will last past the Viaskin Peanut BLA resubmission in Q3, she noted. Bayko, who continues to recommend DBV as she views FDA acceptance of the BLA later this year as a major de-risking event, keeps an Outperform rating and $20 price target on the stock.
03/06/19
STFL
03/06/19
NO CHANGE
Target $10
STFL
Hold
Stifel keeps Hold on DBV pending execution, capital overhang removal
Not much was new in DBV Technologies' earnings press release and the several additional management departures are "probably not a huge surprise" given new CEO, Daniel Tasse, recently took the helm, Stifel analyst Derek Archila tells investors in a post-earnings research note. The analyst remains on the sidelines with a Hold rating and $10 price target until management executes on its near-term regulatory initiatives and addresses its current capital overhang. Archila, however, says DBV's risk/reward is "probably more favorable at these levels" if management is able to re-file its biologics license application on time in Q3, gain BLA acceptance from the FDA and its panel meeting is eventually positive.
03/08/19
HCWC
03/08/19
NO CHANGE
Target $25
HCWC
Buy
DBV resubmission of BLA could be 'meaningful catalyst,' says H.C. Wainwright
H.C. Wainwright analyst Andrew Fein says that with the manufacturing update in February, as well as Julie O'Neil's engagement with the process, he does not foresee any other roadblocks as DBV Technologies moves towards the resubmission of its Biologics License Application in Q3. DBV should "now have the right stewardship to remedy the issues at hand," Fein tells investors in a research note. He thinks a "smooth and successful" execution of the BLA resubmission could reinvigorate investors' confidence in the management team, remove the regulatory overhang, and be a "meaningful catalyst" for the shares. The analyst reiterates a Buy rating on DBV Technologies with a $25 price target.
04/10/19
STFL
04/10/19
NO CHANGE
STFL
Hold
ICER draft report presents modest headwind for DBV, Aimmune, says Stifel
Stifel analyst Derek Archila noted that ICER, an independent and non-partisan research organization that analyzes the benefits along with costs of treatments, issued a draft report assessing the value and effectiveness of Aimmune's (AIMT) AR101 and DBV Technologies' (DBVT) Viaskin peanut for peanut allergy. He believes ICER's cost-effectiveness analysis re-affirms his cautious approach on the peanut immunotherapy category and believes the report presents a modest headwind for the stocks. However, this was only a draft report in which ICER made assumptions for costs since no official pricing has been announced for either therapy, Archlia noted. He maintains Hold ratings on both Aimmune and DBV Technologies.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.